AstraZeneca plc (ADR) (NYSE:AZN)

CAPS Rating: 3 out of 5

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

Results 1 - 20 of 112 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar JCG (< 20) Submitted: 5/26/2014 6:14:42 PM : Outperform Start Price: $71.03 AZN Score: +0.49

Astrazeneca makes lots of money

Recs

0
Member Avatar cajun1958 (33.66) Submitted: 5/25/2014 7:17:29 PM : Underperform Start Price: $71.03 AZN Score: -0.49

Whatever value PFE's merger attempt brought to light in AZN, it appears doubtful the company will be much more than a good yield instrument with a top end in the low 70s,

Recs

0
Member Avatar afewgoodstocks11 (29.85) Submitted: 2/21/2014 1:43:37 PM : Outperform Start Price: $39.41 AZN Score: +30.72

Div. (Yield) $2.70 (3.1%)
Current Yield . . . . . . 6.855%

Recs

0
Member Avatar Teacherman333 (40.43) Submitted: 7/25/2013 11:42:21 AM : Outperform Start Price: $48.85 AZN Score: +30.05

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 25.84%
Trailing PE 10.03
PB 2.83
Div yield 7.60%

Recs

0
Member Avatar IlluminatInvest (70.35) Submitted: 3/18/2013 5:02:08 PM : Outperform Start Price: $43.94 AZN Score: +40.79

Restructuring will cut fat while they restock their drug pipeline, and should eventually allow them to continue raising their dividend.

Recs

0
Member Avatar IlanBigfoot (94.35) Submitted: 12/30/2012 10:45:05 PM : Outperform Start Price: $42.47 AZN Score: +32.36

High yield strategy: TMFHighYield says to look for "high dividend payers from the S&P 500 from diverse sectors, relatively low debt, and a history of increasing dividend payments." This is my Health Care pick.
$46.88

Recs

1
Member Avatar gsauter157 (< 20) Submitted: 8/28/2012 9:05:49 AM : Outperform Start Price: $42.61 AZN Score: +33.32

New CEO

Recs

1
Member Avatar rainmaker59 (38.01) Submitted: 7/17/2012 3:19:51 PM : Outperform Start Price: $41.32 AZN Score: +33.85

Meets my metrics of low PE, high yield, eps, beta, roe and net profit. And 10 percent below 52-week high.

Recs

1
Member Avatar ihaveabaddober (38.22) Submitted: 5/23/2012 3:48:43 PM : Outperform Start Price: $36.54 AZN Score: +52.40

DIVIDEND/ROE MONSTER

Recs

0
Member Avatar outoffocus (22.85) Submitted: 4/27/2012 2:39:36 PM : Outperform Start Price: $38.93 AZN Score: +48.98

low p/e high div yield

Recs

0
Member Avatar Buffettinvestor (61.39) Submitted: 4/3/2012 3:01:59 PM : Outperform Start Price: $40.03 AZN Score: +44.21

Very cheap stock, with under 6 p/e, but still earning incredible returns on capital. Has been hit too hard among the pharmaceutical firms. Great contrarian play, with a great dividend Yield of over 6%.

Recs

0
Member Avatar recklessfier (< 20) Submitted: 3/8/2012 2:14:42 AM : Outperform Start Price: $40.03 AZN Score: +39.69

FDL1

Recs

0
Member Avatar campwt00global (36.82) Submitted: 1/4/2012 8:41:56 AM : Outperform Start Price: $40.57 AZN Score: +26.62

http://seekingalpha.com/article/317243-the-5-yield-solution

Recs

0
Member Avatar ETMatyahoo (44.47) Submitted: 12/23/2011 5:43:07 PM : Outperform Start Price: $39.41 AZN Score: +30.72

Note to self: "actually" in at 44.ish in this week - late Fool-tracking. Sad disclosure!

AZN's the maker of Seroquel and Mysoline, two really far out psychiatric neurological drugs. So I hear.

Recs

1
Member Avatar Chemdawg (70.08) Submitted: 10/8/2011 1:57:28 PM : Outperform Start Price: $40.10 AZN Score: +16.17

buybacks...great yield.... 10% off 52 week low

Recs

0
Member Avatar jmt587 (99.88) Submitted: 9/22/2011 2:10:02 PM : Outperform Start Price: $36.34 AZN Score: +26.99

Long Term Outperform.

Recs

0
Member Avatar d0w0kelley (< 20) Submitted: 8/28/2011 12:27:40 AM : Outperform Start Price: $39.70 AZN Score: +20.68

Large Cap stock trading above their 14-day SMA

Recs

0
Member Avatar STORMSTOCKER (< 20) Submitted: 8/11/2011 4:58:55 PM : Outperform Start Price: $38.29 AZN Score: +25.92

A MAJOR DRUG COMPANY THAT HAS BEEN BEATEN DOWN.

Recs

0
Member Avatar GarlicEater7 (< 20) Submitted: 8/10/2011 7:38:03 PM : Outperform Start Price: $35.85 AZN Score: +31.45

Oversold on panic. New blood thinner won USDA approval last month and should lead to better profits in future reports. Great buy in price.

Recs

0
Member Avatar mrindependent (88.77) Submitted: 7/29/2011 5:41:11 PM : Outperform Start Price: $41.22 AZN Score: +28.09

Effort to pick good longterm stocks

Results 1 - 20 of 112 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement